Erin D. Michos, MD, MHS

Erin Michos, MD examines unique HFpEF mechanisms for women and implications for sex-specific treatment.

Panelists discuss how pediatric lipid screening remains underutilized despite current recommendations and explore practical strategies to increase screening rates and identify cardiovascular risk factors early in childhood.

Panelists discuss how elevated LDL-C levels significantly contribute to ASCVD development through both modifiable lifestyle factors and genetic predisposition, making it a critical target for cardiovascular disease prevention.

Panelists discuss how effective management of dyslipidemia through adherence to AHA guidelines is crucial for reducing cardiovascular mortality rates and improving patient outcomes.

Panelists discuss how cardiovascular disease remains a leading health concern in the United States, examining its rising prevalence, risk factors such as dyslipidemia, and management strategies aligned with AHA guidelines to reduce patient mortality.

The panelists stress the significance of a comprehensive approach to patient care, acknowledging the interconnected nature of cardiovascular, kidney, endocrine, and obesity-related benefits, and highlighting that addressing secondary diseases can minimize overall disease risk in patients.

Michael Koren, MD addresses the challenges posed by prior authorization and the diminished role of pharmaceutical sales representatives in informing providers about medication advancements, leading to a disconnect in the provider's treatment arsenal.

The panel explores issues surrounding medication adherence and the potential for improved patient engagement. They emphasize that poor medication adherence increases the risk of cardiovascular events and discuss factors such as drug cost, timing of administration, and the importance of adopting a patient-centric approach to optimize treatment success.

Michael Blaha, MD, highlights the potential of GLP-1 agonists in lowering LDL cholesterol, triglycerides, and body weight in patients with diabetes, presenting them as an additional option for reducing cardiovascular risk in this patient population.

The panel of medical experts addresses the challenges in raising awareness among healthcare providers about various medications and the need for increased awareness of the REDUCE-IT trial outcomes.

Erin Michos, MD, highlights several notable emerging lipid-lowering treatments, including bempedoic acid, the ANGPTL3 inhibitor evinacumab, the MTP inhibitor lomitapide, the ApoB-100 inhibitor mipomersen, and the ApoC-III degradation molecules volanesorsen and olezarsen.

Michael Koren, MD, discusses the recently released results from the VICTORIAN-INITIATE (V-INITIATE) trial, which were presented at the 2024 American College of Cardiology (ACC) Annual Scientific Session in Atlanta.

Deepak Bhatt, MD, MPH, MBA, reviews the efficacy and safety data of inclisiran, highlighting its long-term effects and noting that injection site reactions are among the most prominent adverse reactions associated with this medication.

Michael Blaha, MD, discusses the efficacy and safety of novel targeted therapies for lowering LDL cholesterol and emphasizes the importance of long-term data in building patient confidence in this new treatment option.

Leading experts highlight the established role of PCSK9 inhibitors, such as evolocumab and alirocumab, and introduce the promising second-generation PCSK9 inhibitors, known as small interfering RNA (siRNA), which represent an innovative therapeutic approach that selectively reduces the production of specific proteins through RNA interference.

Panelists discuss ongoing clinical trials aimed at lowering Lipoprotein(a) levels, emphasizing the importance of proactive patient testing, and referring to new guidelines recommending that everyone be tested once in their lifetime.

Key opinion leaders in cardiology share insights on reducing LDL cholesterol to manage cardiovascular disease risk, educating patients not reaching goals, and implementing real-world clinical strategies for maintaining lower LDL levels.

Erin Michos, MD, delivers a comprehensive review of lipid management and its influence on cardiovascular disease, emphasizing recent studies that underscore the need for improved treatment strategies for high-risk patients.

A panel of expert cardiologists share their clinical pearls for managing patients with hyperlipidemia.

Medical experts discuss the importance of screening for Lp(a) and ongoing trials targeting this protein. Moreover, other new targets for the treatment of hyperlipidemia are reviewed.

Drs Michos, McGowan, and Kohli discuss Lp(a) and the development of cardiovascular disease.

Drs Kohli and McGowan review recently published long-term efficacy and safety data on the use of a PCSK9-inhibitor.

The panelists discuss how and when to use combination therapy in patients with hyperlipidemia.

Dr Michos discusses safety and efficacy of available nonstatin therapies and emerging agents for treating hyperlipidemia.

Cardiologists discuss managing statin intolerance in clinical practice, highlighting the importance of creating individualized plans and when to initiate nonstatin therapies.

Expert cardiologists discuss data on gender, racial, and ethnic disparities and how to address them in the management of hyperlipidemia.

The cardiology panelists discuss the importance of screening patients for hyperlipidemia and familial hypercholesterolemia.

The reasons many patients do not reach LDL-cholesterol thresholds.

Mary McGowan, MD, FNLA, reviews real-world data from the Family Heart Database on the clinical consequences of failing to reach LDL-C thresholds.

Mary McGowan, MD, FNLA, discusses real-world data from the Family Heart Database on achieving LDL-C thresholds.